Physician profile
Alan W Brewer
NPI 1760400832
$3,194.13
in general payments reported to CMS, 2019-2025
37 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $271 · 2021: $62.90 · 2023: $698 · 2024: $873 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.80 | 2023-2024 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $383.23 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $354.48 | 2019-2024 | |
| Amgen INC. | $246.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Stimwave Technologies Incorporated | $180.43 | 2019 | |
| Astellas Pharma US INC | $179.70 | 2020-2025 | Veozah |
| Novo Nordisk INC | $139.48 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $129.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $116.42 | 2023-2024 | Shingrix, Arexvy, Rotarix |
| Daiichi Sankyo INC. | $111.26 | 2019-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.46 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $76.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.25 | 2019-2020 | |
| Tris Pharma INC | $71.81 | 2023 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $58.50 | 2024 | Voquezna |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.